Research paper
The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized, double-blind, placebo-controlled trial
Study answer
What this study found
MK-7 did not reduce vascular calcification. The primary 18F-NaF PET outcome showed a change in TBR of 0.25 versus placebo, with a 95% CI of -0.02 to 0.51 and P = 0.06. CT calcification mass also showed no treatment effect, with a change of 0.50, 95% CI of -0.23 to 1.36, and P = 0.18. Despite a marked reduction in dp-ucMGP at 3 and 6 months, no adverse events were reported and the authors concluded that further work is needed to interpret 18F-NaF PET activity in this setting.
- Study & population
- Randomized, double-blind, placebo-controlled trial conducted in the Netherlands.
- Intervention
- Menaquinone-7 (MK-7) 360 μg orally once daily for 6 months, given as two tablets taken with the evening meal.
- Key limitation
- The trial was relatively small and only 6 months long, limiting power for clinical and imaging outcomes.
View source
Open PDFOriginal abstract
ABSTRACT Background Vitamin K occurs in the diet as phylloquinone and menaquinones. Observational studies have shown that both phylloquinone and menaquinone intake might reduce cardiovascular disease (CVD) risk. However, the effect of vitamin K on va…